# Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer

Source: https://onco.cc/trials/nct07805252/  
OnCo record `nct07805252` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ODM-216 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.

## Summary

Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer is a phase 1/2 interventional study registered as NCT07805252 by Orion Corporation, Orion Pharma, with 195 participants planned, started 2026-09-03 and due to reach its primary completion in 2028-01-10. Interventions recorded: ODM-216.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07805252
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours
- Sponsor: Orion Corporation, Orion Pharma
- Enrolled: 195

## Sources

- ClinicalTrials.gov NCT07805252: https://clinicaltrials.gov/study/NCT07805252

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07805252.json